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A COMPARATIVE STUDY OF EFFICACY AND SAFETY OF TOPICAL     
MOMETASONE 0.1% WITH PLACENTAL EXTRACT VERSUS 
TOPICAL MOMETASONE 0.1% WITH TOPICAL TACROLIMUS 0.1% 
IN VITILIGO 
ABSTRACT 
BACKGROUND: 
       Vitiligo is an idiopathic , acquired , depigmentation disorder of the skin and 
hair . Vitiligo is one of the commonest skin disorder affecting about 1 to 2 % of 
world population . Typical vitiligo lesions are characterised by milky white , non 
scaly macules with clearly defined margins . For stable vitiligo ,  where the 
involvement of depigmented macules is less than 20 % of  Body surface area , 
the main modality of treatment is topical steroids with adjunctive treatment. 
Topical tacrolimus , an immunomodulator , calcineurin inhibitor added to the 
newer armemantarium in treatment of vitiligo.  In this study Efficacy and Safety 
of topical tacrolimus in combination with topical mometasone was well studied 
and compared with standard treatment, topical mometasone with topical placental 
extract.  
 
 
 
AIM AND OBJECTIVE: 
       To determine and compare the efficacy and safety of topical mometasone 
0.1% with topical placental extract versus topical mometasone 0.1% with topical 
tacrolimus 0.1%    in terms of repigmentation in  vitiligo patients. 
METHODS: 
      Single centered , openlabel, randomized, comparative , interventional parallel 
arm study. This study was conducted in dermatology OPD , govt Stanley medical 
college Chennai for a duration of 28 weeks . Among 80 patients included in the 
study , 41 patients in group A received standard treatment of topical mometasone 
0.1% with topical placental extract and 39 patients in group B received topical 
mometasone 0.1% with topical tacrolimus0.1% . Efficacy was determined in 
terms difference in mean VASI score between two groups and percentage 
repigmentation rate between two groups groups  from baseline  and  at  the end 
of 2nd , 4th , 8th , 12th, 24th  weeks. Adverse events were closely monitored.   
RESULTS: 
        In our study, totally 124 patients were screened , 44 patients were excluded, 
80 patients participated in the study . 41 patients in group A received standard 
treatment and 39 patients in the study group received topical mometasone with 
topical tacrolimus for 24 weeks . mean VASI score at baseline was 10.58 in group 
A and 10.82 in group B (P=0.7170) which was comparable . At the end of 24 
weeks mean VASI score , mean VASI score in group A was 5.66 and group B 
was 3.56 where there is significant difference in the reduction of mean VASI 
score between two groups(P=0.0027) . Percentage repigmentation rate were 
higher in the group B  , in which 19 patients(48.71%) in group B had excellent 
repigmentation(grade IV) whereas only 2 patients(4.87%) had grade IV 
repigmentation in group A.  From the results, it was clear that combination 
therapy of topical mometasone with topical tacrolimus were having significantly 
beneficial effects than standard treatment 
CONCLUSION: 
     In this study , topical tacrolimus 0.1% used  with topical mometasone 0.1% is 
a better combination therapy in producing repigmentation and  clinical 
improvement in stable vitiligo patients. Topical Tacrolimus 0.1% is a well 
tolerated and  effective adjunctive therapy with topical mometasone for stable 
vitiligo. 
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